Clinical Usefulness and Influence on Esophageal Motility of Pyridostigmine for Dysphagia in Systemic Sclerosis

NCT06915181 | Withdrawn Phase 2

• 1 other identifier: PySyS
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Systemic sclerosis is characterized by progressive fibrosis of different organ systems. With a longer duration, the risk of gastrointestinal involvement increases. There is a high prevalence of gastro-esophageal reflux disease (GERD) secondary to a severe insufficiency of the lower esophageal sphincter (LES), resulting in severe reflux esophagitis when left untreated. On the long run, this is associated with an elevated risk of esophageal bleeding, peptic stenosis, Barrett esophagus and associated risk of esophageal cancer. Apart from the insufficiency of the LES, esophageal aperistalsis is frequently observed. This results in prolonged esophageal contact with the refluxate due to insufficient clearance by the absence of adequate peristalsis. As a consequence of impaired peristalsis, patients with esophageal involvement in systemic sclerosis often experience dysphagia for solids, causing weight loss and malnu-trition, and reducing in quality of life. To control reflux disease, high dose proton pump inhibitor therapy is part of the advocated treatment for esophageal involvement in systemic sclerosis. This therapy is highly effective in reducing acidic reflux, but has no influence on the esophageal motility disorder, leaving the dysphagia untreated. Because of the lack of a specific treatment targeting dysphagia, most patients eventually are advised to take conservative measures such as eating while sitting up straight, chewing well and flushing every food bolus with fluids. While current treatment targets the acidic reflux, there is no accepted treatment to improve esophageal motility. In the presence of dysphagia patients are advocated to follow conservative measures like sitting upright when eating and drinking water to help passage of the bolus. A cholinesterase inhibitor, pyridostigmine prevents the degradation of acetyl choline at the neuromuscular junction, prolonging its excitatory action. A recent uncontrolled study in patients suffering from systemic sclerosis identified a beneficial effect on gastro-intestinal symptoms, especially constipation. In healthy volunteers intake of pyridostigmine enhanced esophageal contractility as revealed by an increased amplitude of distal esophageal con-tractions. Despite this beneficial influence on esophageal motility there are no data on the possible therapeutic effects in patients with systemic sclerosis and esophageal involvement. This study aims at evaluating the effects of pyridostigmine on symptoms of dysphagia. Additionally improvement of GERD symptoms and quality of life will be recorded. Improvement of parameters of esophageal motility as well as baseline esophageal impedance during esophageal contraction will also be assessed.

Conditions

Systemic Sclerosis With Dysphagia

Outcome Measures

Primary Outcomes (1)

• difference in FSSG score

  decrease in FSSG score between treatment arms

  from baseline till visit 4 (week 10)

Secondary Outcomes (8)

• difference in BEDQ score

  from baseline till visit 4 (week 10)

• change in quality of life between treatment arms

  from baseline till visit 4 (week 10)

• changes in high resolution manometry between treatment arms

  from baseline till visit 4 (week 10)

• changes in high resolution manometry between treatment arms

  from baseline till visit 4 (week 10)

• changes in high resolution manometry between treatment arms

  from baseline till visit 4 (week 10)

Study Arms (2)

Placebo first-then Pyridostigmine

PLACEBO COMPARATOR

Drug: Pyridostigmine

Pyridostigmine first-then Placebo

ACTIVE COMPARATOR

Drug: Pyridostigmine

Interventions

Pyridostigmine DRUG

Subjects will participate in a double-blind randomized controlled cross-over trial. All patients will receive the study drug and placebo. Subjects and investigators will remain blinded to whether the subject receives active treatment during the first or second treatment period. Participation in the study will last 10 weeks, with 4 weeks on active treatment and 4 weeks on placebo, with a 2-week wash-out period in between.

Placebo first-then Pyridostigmine; Pyridostigmine first-then Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged 18 years or older;
• Known systemic sclerosis;
• Dysphagia with BEDQ score of 10 or more despite twice daily high dose PPI (omeprazole 40 mg b.i.d., esomeprazole 20 mg b.i.d., pantoprazole 40 mg b.i.d., lansoprazole 30 mg b.i.d.).

You may not qualify if:

• Presence of reflux oesophagitis grade C or more, eosinophilic oesophagitis, oesophageal stenosis (whether peptic or malignant);
• Prior oesophageal surgery, endoscopic resections, Radiofrequency Abla-tion for Barrett's mucosa or POEM;
• Prior gastric surgery;
• Prior diagnosis of major oesophageal motor disorder such as oesophageal spasm, achalasia, EGJ outflow obstruction;
• Diarrhoea (defined as Bristol Stool Scale \> 5) for more than 2 days per week in the past 2 weeks;
• Uncontrolled asthma, exacerbation of COPD in the last 4 weeks;
• Known ischaemic heart condition or myocardial infarction in the last 4 weeks;
• Resting heart rate \< 60 bpm;
• AV-block 2 or 3 (except after implantation of a pacemaker), or bradycardia \< 60 bpm;
• Systolic blood pressure \> 100 mmHg;
• Impaired renal function with glomerular filtration rate \< 30 ml/min;
• Prior or current urinary obstruction;
• Previous treatment with pyridostigmine in the past 4 weeks;
• Treatment with anticholinergic agents in the past 4 weeks;
• Treatment with prokinetic agents during the past 4 weeks

Sponsors & Collaborators

• Universitair Ziekenhuis Brussel: lead

MeSH Terms

Interventions

Pyridostigmine Bromide

Intervention Hierarchy (Ancestors)

Pyridinium Compounds; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 18, 2023
• First Posted: April 8, 2025
• Study Start: December 1, 2023
• Primary Completion: May 1, 2024
• Study Completion: May 1, 2024
• Last Updated: April 8, 2025

Record last verified: 2025-03